ING Groep NV Has $2.36 Million Stock Holdings in Insulet Corporation $PODD

ING Groep NV decreased its stake in Insulet Corporation (NASDAQ:PODD) by 52.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 8,291 shares of the medical instruments supplier’s stock after selling 9,009 shares during the period. ING Groep NV’s holdings in Insulet were worth $2,357,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC increased its stake in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the period. Elyxium Wealth LLC acquired a new stake in shares of Insulet in the fourth quarter valued at about $28,000. Fideuram Asset Management Ireland dac acquired a new stake in shares of Insulet in the fourth quarter valued at about $41,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Insulet in the third quarter valued at about $49,000. Finally, Osterweis Capital Management Inc. acquired a new stake in shares of Insulet in the second quarter valued at about $51,000.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PODD. JPMorgan Chase & Co. decreased their price target on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research note on Thursday, May 7th. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price target (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Sanford C. Bernstein decreased their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Evercore cut their target price on Insulet from $240.00 to $200.00 in a research report on Thursday, May 7th. Finally, Bank of America cut their target price on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Twenty-one investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $250.00.

Insulet Price Performance

PODD stock opened at $159.61 on Wednesday. The stock has a market capitalization of $11.05 billion, a PE ratio of 37.12, a price-to-earnings-growth ratio of 1.19 and a beta of 1.13. The company’s 50-day moving average is $173.43 and its 200-day moving average is $235.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. Insulet Corporation has a 1 year low of $140.63 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s revenue was up 33.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts expect that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Insider Transactions at Insulet

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.